Ocular Therapeutix (Ocular Therapeutix) Total Current Assets : $232.24 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Ocular Therapeutix's total current assets for the quarter that ended in Dec. 2023 was $232.24 Mil.

Ocular Therapeutix Total Current Assets Historical Data

The historical data trend for Ocular Therapeutix's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Total Current Assets Chart

Ocular Therapeutix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

60.17

246.16

191.30

129.63

232.24

Ocular Therapeutix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															129.63	107.16	100.71	141.26	232.24

Ocular Therapeutix Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Ocular Therapeutix's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	195.807	+	26.179	+	2.305	+	7.944
	=	232.24

Ocular Therapeutix's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	195.807	+	26.179	+	2.305	+	7.944
	=	232.24

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Ocular Therapeutix (NAS:OCUL) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Ocular Therapeutix's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	195.807	-	160.929	+	0.75 * 26.179	+	0.5 * 2.305
=	55.66

Ocular Therapeutix Total Current Assets Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocular Therapeutix (Ocular Therapeutix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

0OT:Germany 0OT:Germany

Address

24 Crosby Drive, Bedford, MA, USA, 01730

Website

https://www.ocutx.com

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Executives

Summer Road Llc	10 percent owner	207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden	officer: Chief Medical Officer	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger	officer: General Counsel	24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman	officer: Chief Financial Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White	officer: Chief Business Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen	officer: Chief Operations Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney	director, 10 percent owner, officer: President and CEO	C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730